B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Which Pre-CAR-T chemo is safer? new trial aims to find out
Disease control Not yet recruitingThis trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 23, 2026 19:17 UTC
-
New pill aims to keep lymphoma away after CAR-T
Disease control Not yet recruitingThis study tests whether taking zanubrutinib (a targeted cancer pill) for two years after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults whose cancer responded to CAR-T will receive the drug. The main goal is to see how many remain …
Matched conditions: B-CELL LYMPHOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 23, 2026 19:17 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. T…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New combo therapy targets hard-to-treat blood cancers
Disease control Not yet recruitingThis study tests a new drug called NX-5948 combined with other medicines for adults with certain blood cancers (B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma). About 150 people will join to see if the combination is safe and works. The goal is to co…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Not yet recruitingThis study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to attack cancer cells with two targets (CD19 and CD22). It is for adults with leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to check safety and how well t…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in adults with B-cell cancers (like certain lymphomas) that have come back or not responded to prior treatments. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safes…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Double-Pronged CAR t cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check the safety …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC